JNCCN 360 - Bladder - Available Clinical Trials

Editor:

Thomas Flaig, MD

Advertisement

Advertisement

Available Clinical Trials

A Multicenter, Open-label Phase 1/2 Study of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations (SURF-301)

A Phase II Study of Avelumab in Combination with Bladder-Directed Radiation in Cisplatin-Ineligible Patients with Muscle-Invasive Urothelial Carcinoma of the Bladder

A Phase II Study of Intermittent Checkpoint Inhibitor Therapy in Patients with Advanced Urothelial Carcinoma

A Phase II Trial of Atezolizumab and Bevacizumab in Cisplatin-ineligible Patients with Advanced/Unresectable Urothelial Cancer

A Phase III Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer

Biomarker Identification for Bladder Cancer Patients

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

Pembrolizumab in MIBC

Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized MIBC

Study of CAbozantinib in Combination With AtezolizumaB for Muscle-Invasive BladdEr Cancer (ABATE)

Study of CG0070 Given in Patients With Non-MIBC, Unresponsive to Bacillus-Calmette-Guerin

Tissue and Body Fluid Analysis from Patients with Bladder Cancer and Other Urothelial Cancers of the Urinary Tract

Sections

NCCN Resources

Copyright © 2023 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.